Figure 2.
mPFS according to the line of treatment. The mPFS was 11.6 (95% CI, 5.8-17.3), 9.7 (95% CI, 7.7-10.8) and 7.5 (95% CI, 6.0-9.8) months for patients treated with Exe-Eve as first, second or third line of treatment, respectively. mPFS, median progression-free survival; Eve-Exe, Everolimus-Exemestane; CI, confidence interval.